Mesothelioma Medical

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Background:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This is a Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have malignant mesothelioma.

Objectives:

	Determine the antitumor activity of gemcitabine and epirubicin in patients with malignant pleural mesothelioma.
	Determine the toxicity of this regimen in this patient population.
	Determine the time to progression and overall survival of patients treated with this regimen.
	Assess quality of life in patients treated with this regimen.

Location/Contact Information:
Arizona
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, 85259-5404, United States;
Recruiting
Tom Robert Fitch, MD 480-301-7010

Florida
Mayo Clinic, Jacksonville, Florida, 32224, United States;
Recruiting
Edith A. Perez, MD 507-284-2511
perez.edith@mayo.edu

Illinois
CCOP - Carle Cancer Center, Urbana, Illinois, 61801, United States; Recruiting
Kendrith M. Rowland, MD 217-383-3394

CCOP - Illinois Oncology Research Association, Peoria, Illinois, 61602, United States; Recruiting
John W. Kugler, MD 309-636-3605
Iowa
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, 52403-1206, United States;
Recruiting
Martin Wiesenfeld, MD 319-363-8303

CCOP - Iowa Oncology Research Association, Des Moines, Iowa, 50309-1016, United States;
Recruiting
Roscoe F. Morton, MD 515-244-7586
Siouxland Hematology-Oncology, Sioux City, Iowa, 51101-1733, United States; Recruiting
John C. Michalak, MD 712-252-0088 shoa@pionet.net

Kansas
CCOP - Wichita, Wichita, Kansas, 67214-3882, United States;
Recruiting
Shaker R. Dakhil, MD 316-262-4467
Louisiana
CCOP - Ochsner, New Orleans, Louisiana, 70121, United States;
Recruiting
Carl G. Kardinal, MD 504-842-3910
Michigan
CCOP - Ann Arbor Regional, Ann Arbor, Michigan, 48106, United States; Recruiting
Philip J. Stella, MD 734-712-1000
Minnesota
CentraCare Health Plaza, Saint Cloud, Minnesota, 56303, United States; Recruiting
Harold E. Windschitl, MD 320-229-5199
schosp@cloudnet.com

Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States; Recruiting
Jeff Sloan, PhD 507-284-2111
Nebraska
CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, 68106, United States;
Recruiting
James A. Mailliard, MD 402-898-8044
North Dakota
CCOP - Merit Care Hospital, Fargo, North Dakota, 58122, United States; Recruiting
Ralph Levitt, MD 701-234-2397
Ohio
CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, 43623-3456, United States;
Recruiting
Paul L. Schaefer, MD 419-843-6147
Pennsylvania
CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, 17822-2001, United States;
Recruiting
Suresh G. Nair, MD 570-271-6413
South Dakota
CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, 57104, United States;
Recruiting
Loren K. Tschetter, MD 605-328-8000

Rapid City Regional Hospital, Rapid City, South Dakota, 57709, United States; Recruiting
Larry P. Ebbert, MD 605-341-8704
Study chairs or principal investigators
Scott Okuno, MD, Study Chair
Mayo Clinic Cancer Center